Integrating mpMRI and 18F-PSMA PET/CT via the composite P score to detect clinically significant prostate cancer in the PSA gray zone

Biopsy triage remains challenging in men with prostate-specific antigen (PSA) levels of 4.0–10.0 ng/mL because multiparametric MRI (mpMRI) may yield equivocal findings and reader-dependent interpretation. Prostate-specific membrane antigen (PSMA) PET/CT may provide complementary molecular information. We evaluated the diagnostic performance and incremental value of the composite P score, which integrates PI-RADS and PRIMARY scores, for detecting clinically significant prostate cancer (csPCa) in the PSA gray zone. This two-center retrospective study included 178 men with PSA 4.0–10.0 ng/mL who underwent mpMRI, 18 F-PSMA PET/CT, and biopsy between January 2021 and December 2024. Junior and senior radiologists independently assigned Prostate Imaging Reporting and Data System (PI-RADS) scores. A single PRIMARY score was assigned for PSMA PET/CT based on two independent nuclear medicine reads, with discrepancies adjudicated. Composite P scores combined each radiologist’s PI-RADS assessment with the PRIMARY score. csPCa was defined as Gleason score ≥ 3 + 4 according to prostate biopsy. Performance was assessed using area under the curve (AUC), net reclassification improvement (NRI), and decision curve analysis (DCA). csPCa was detected in 125/178 patients (70.2%). Compared with PI-RADS alone, the composite P score showed a higher AUC for the junior reader (0.769 vs. 0.661; P = 0.014), while the difference was not significant for the senior reader (0.805 vs. 0.744; P = 0.167). At the threshold of ≥ 3, the composite P score achieved 100% sensitivity (125/125) for both readers. NRI was significant for the junior reader (0.175; P = 0.010) but not for the senior reader. DCA showed higher estimated net benefit than PI-RADS alone across clinically relevant threshold probabilities for both readers. The composite P score showed favorable performance for csPCa in the PSA gray zone. Integrating 18 F-PSMA PET/CT with mpMRI may provide complementary diagnostic information for biopsy triage in selected patients.

Authors

Institutions

Publication Details

Journal
BMC Medical Imaging
Published
2026-11-14
DOI
https://doi.org/10.1186/s12880-026-03042-3
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrating mpMRI and 18F-PSMA PET/CT via the composite P score to detect clinically significant prostate cancer in the PSA gray zone

Yachao Liu, Chen Wen, 陳玉玲, Wang Zhongyi et al.
BMC Medical Imaging
Prostate Cancer Diagnosis and Treatment
article

Integrating mpMRI and 18F-PSMA PET/CT via the composite P score to detect clinically significant prostate cancer in the PSA gray zone

Yachao Liu, Chen Wen, 陳玉玲, Wang Zhongyi, Weilong Li, Xiaojing Zhang, Haiyi Wang, Jian Zhao, Xu Bai, XiaoHui Ding, HongHao Xu, RuiMin Wang, BaiChuan Liu
article en

Abstract

Biopsy triage remains challenging in men with prostate-specific antigen (PSA) levels of 4.0–10.0 ng/mL because multiparametric MRI (mpMRI) may yield equivocal findings and reader-dependent interpretation. Prostate-specific membrane antigen (PSMA) PET/CT may provide complementary molecular information. We evaluated the diagnostic performance and incremental value of the composite P score, which integrates PI-RADS and PRIMARY scores, for detecting clinically significant prostate cancer (csPCa) in the PSA gray zone. This two-center retrospective study included 178 men with PSA 4.0–10.0 ng/mL who underwent mpMRI, 18 F-PSMA PET/CT, and biopsy between January 2021 and December 2024. Junior and senior radiologists independently assigned Prostate Imaging Reporting and Data System (PI-RADS) scores. A single PRIMARY score was assigned for PSMA PET/CT based on two independent nuclear medicine reads, with discrepancies adjudicated. Composite P scores combined each radiologist’s PI-RADS assessment with the PRIMARY score. csPCa was defined as Gleason score ≥ 3 + 4 according to prostate biopsy. Performance was assessed using area under the curve (AUC), net reclassification improvement (NRI), and decision curve analysis (DCA). csPCa was detected in 125/178 patients (70.2%). Compared with PI-RADS alone, the composite P score showed a higher AUC for the junior reader (0.769 vs. 0.661; P = 0.014), while the difference was not significant for the senior reader (0.805 vs. 0.744; P = 0.167). At the threshold of ≥ 3, the composite P score achieved 100% sensitivity (125/125) for both readers. NRI was significant for the junior reader (0.175; P = 0.010) but not for the senior reader. DCA showed higher estimated net benefit than PI-RADS alone across clinically relevant threshold probabilities for both readers. The composite P score showed favorable performance for csPCa in the PSA gray zone. Integrating 18 F-PSMA PET/CT with mpMRI may provide complementary diagnostic information for biopsy triage in selected patients.

BMC Medical Imaging
Capital Medical University (CN), Chinese PLA General Hospital (CN), Yuhuangding Hospital (CN), Beijing Hospital of Traditional Chinese Medicine (CN)
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon